Corcept Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	761.41	675.04	482.38	401.86	365.98
Revenue Growth (YoY)	12.79%	39.94%	20.04%	9.80%	3.42%
Cost of Revenue	12.98	10.88	6.48	5.39	5.28
Gross Profit	748.43	664.16	475.89	396.47	360.7
Selling, General & Admin	448.73	280.32	184.26	152.85	122.36
Research & Development	254.91	246.89	184.35	130.99	113.86
Other Operating Expenses	-	-	-	28	-
Operating Income	44.8	136.95	107.28	112.63	124.48
Interest Income	21.67	24.54	17.28	3.56	0.53
Total Non-Operating Income (Expense)	21.67	24.54	17.28	3.56	0.53
Pretax Income	66.46	161.49	124.56	116.19	125.01
Provision for Income Taxes	-33.19	20.28	18.42	14.77	12.49
Net Income	98.17	139.73	105.5	101.29	112.51
Net Income to Common	98.17	139.73	105.5	101.29	112.51
Net Income Growth	-29.74%	32.45%	4.15%	-9.98%	6.13%
Shares Outstanding (Basic)	104	103	104	107	116
Shares Outstanding (Diluted)	120	113	112	116	126
Shares Change (YoY)	5.73%	1.55%	-3.64%	-7.94%	1.42%
EPS (Basic)	0.95	1.35	1.02	0.95	0.97
EPS (Diluted)	0.82	1.23	0.94	0.87	0.89
EPS Growth	-33.33%	30.85%	8.05%	-2.25%	4.71%
Free Cash Flow	141.79	196.12	126.54	119.91	167.42
Free Cash Flow Growth	-27.71%	54.99%	5.53%	-28.38%	11.07%
Free Cash Flow Per Share	1.18	1.73	1.13	1.03	1.33
Gross Margin	98.30%	98.39%	98.66%	98.66%	98.56%
Operating Margin	5.88%	20.29%	22.24%	28.03%	34.01%
Profit Margin	13.09%	20.92%	22.00%	25.24%	30.74%
FCF Margin	18.62%	29.05%	26.23%	29.84%	45.75%
EBITDA	45.95	137.75	108.32	113.89	125.96
EBITDA Margin	6.03%	20.41%	22.46%	28.34%	34.42%
EBIT	44.8	136.95	107.28	112.63	124.48
EBIT Margin	5.88%	20.29%	22.24%	28.03%	34.01%
Effective Tax Rate	-49.94%	12.56%	14.79%	12.71%	9.99%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.